

**To:** Kromhout, J. (Hans)[h.kromhout@uu.nl]; Kathryn Guyton[GuytonK@iarc.fr]; Blair, Aaron (NIH/NCI) [V][blaira@exchange.nih.gov]; GMC24@columbia.edu[GMC24@columbia.edu]; Egeghy, Peter[Egeghy.Peter@epa.gov]; Forastiere, Francesco[f.forastiere@deplazio.it]; Lin Fritschi[lin.fritschi@curtin.edu.au]; Jahnke, Gloria (NIH/NIEHS) [E][jahnke@niehs.nih.gov]; Bill Jameson[drjameson@embarqmail.com]; frank lecurieux[frank.lecurieux@echa.europa.eu]; Martin, Matt[Martin.Matt@epa.gov]; John McLaughlin[John.McLaughlin@oahpp.ca]; Teresa Rodriguez[teresar66@gmail.com]; Matthew Ross[MRoss@cvm.msstate.edu]; Rusyn, Ivan[IRusyn@cvm.tamu.edu]; Consolato Sergi[biotechlab@gmail.com]; Mannetje, Andrea[A.Mannetje@massey.ac.nz]; Lauren Zeisel[**(b)(6) personal**]; Christopher Portier[cportier@mac.com]  
**Cc:** imo-pro@iarc.fr[imo-pro@iarc.fr]  
**From:** Isabelle Baldi  
**Sent:** Mon 3/16/2015 7:40:58 AM  
**Subject:** RE: IARC Monograph vol 112- Lancet oncology article draft  
TLO vol 112 13 March2015+HK+IB.docx

Hi Kate and all,

Thank you very much for the draft. I added changes in the attached version revised by Hans: references by Koutros on malathion (Prostate cancer) have to be corrected as mentioned in the comments.

I also have a question to Hans and Linn: would it be useful to mention that glyphosate is not only used in agriculture but also in urban areas (roads, public gardens,...) and in private gardens...?

All the best to you all,

Isabelle

Isabelle BALDI  
Maître de conférences-Praticien Hospitalier  
Laboratoire Santé Travail Environnement - Centre INSERM U 897  
ISPED- Université Bordeaux Segalen  
146 rue Léo Saignat- 33076 BORDEAUX  
+33 5 57 57 12 34

-----Original Message-----

From: "Kromhout, J. (Hans)" <h.kromhout@uu.nl>  
To: Kathryn Guyton <GuytonK@iarc.fr>, Isabelle Baldi <Isabelle.Baldi@isped.u-bordeaux2.fr>, "Blair, Aaron (NIH/NCI) [V]" <blaira@exchange.nih.gov>, "GMC24@columbia.edu" <GMC24@columbia.edu>, "Egeghy, Peter" <Egeghy.Peter@epa.gov>, "Forastiere, Francesco" <f.forastiere@deplazio.it>, Lin Fritschi <lin.fritschi@curtin.edu.au>, "Jahnke, Gloria (NIH/NIEHS) [E]" <jahnke@niehs.nih.gov>, Bill Jameson <drjameson@embarqmail.com>, frank lecurieux <frank.lecurieux@echa.europa.eu>, Matt Martin <martin.matt@epa.gov>, John McLaughlin <John.McLaughlin@oahpp.ca>, Teresa Rodriguez <teresar66@gmail.com>, "Matthew Ross" <MRoss@cvm.msstate.edu>, "Rusyn, Ivan" <IRusyn@cvm.tamu.edu>, Consolato Sergi <biotechlab@gmail.com>, "Mannetje, Andrea" <A.Mannetje@massey.ac.nz>, Lauren Zeisel <**(b)(6) personal**>, "Christopher Portier" <cportier@mac.com>  
Cc: "imo-pro@iarc.fr" <imo-pro@iarc.fr>  
Date: Mon, 16 Mar 2015 06:48:50 +0000

Subject: RE: IARC Monograph vol 112- Lancet oncology article draft

Hi Kathryn,

The write up looks pretty good. In the attachment my comments in track changes in the word document. I missed a few lines (short paragraph) on the issues we wrote up on exposure assessment and the multiple exposure situations all epi-studies have to deal with. I think it would be good to have that in the Lancet Oncology as well.

Best and good luck with the submission, Hans

---

From: Kathryn Guyton [[GuytonK@iarc.fr](mailto:GuytonK@iarc.fr)]  
Sent: Friday, March 13, 2015 3:35 PM  
To: Isabelle Baldi; Blair, Aaron (NIH/NCI) [V]; [GMC24@columbia.edu](mailto:GMC24@columbia.edu); Egeghy, Peter; Forastiere, Francesco; Lin Fritschi; Jahnke, Gloria (NIH/NIEHS) [E]; Bill Jameson; Kromhout, J. (Hans); frank lecurieux; Matt Martin; John McLaughlin; Teresa Rodriguez; Matthew Ross; Rusyn, Ivan; Consolato Sergi; Mannetje, Andrea; Lauren Zeise; Christopher Portier  
Cc: [imo-pro@iarc.fr](mailto:imo-pro@iarc.fr)  
Subject: IARC Monograph vol 112- Lancet oncology article draft

Dear all,

We thank you again for your outstanding contributions to the IARC Monograph volume 112 meeting!

We provide for your review and comment no later than Monday COB in your time zone a draft of the Lancet Oncology article. We ask for your feedback using track changes, preferably using the google doc sent separately or in the appended Word file. Please turn on track changes before entering any suggested edits. We strongly prefer direct edits to the text but will attempt to address any comments as well.

Please be reminded that the information summarised herein is strictly embargoed until the Lancet Oncology article is published online. We will be pleased to inform you when this has occurred.

My very best regards,  
With thanks to you all,  
Kate  
Kate Z. Guyton PhD DABT  
Responsible Officer, Volume 112  
Monographs Section  
International Agency for Research on Cancer  
150, cours Albert Thomas  
69372 Lyon Cedex 08

France

Tel: [+33] (0)4 72 73 86 54

[Guytonk@iarc.fr](mailto:Guytonk@iarc.fr)<mailto:[Guytonk@iarc.fr](mailto:Guytonk@iarc.fr)>